Drug
Biib033
Biib033: highest development phase Phase 2, developed by Biogen. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Biogen
Trials
| Drug | Phase | Indication |
|---|---|---|
| BIIB033 (anti-LINGO-1 mAb) NCT01721161 | Phase 2 | Acute Optic Neuritis |
Latest
No recent events.
Follow Biib033 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.